Figures & data
Table 1. Ongoing clinical trials for Alzheimer disease
Figure 1. Humoral and cellular immune responses generated in mice by DNA-based epitope vaccine using TDS-IM EP system and protein-based AD epitope vaccine formulated with Quil-A adjuvant. (A and B) Cellular responses are specific to Thep protein, but not Aβ40 peptide. Splenocytes were re-stimulated with 10 µg/mL protein or Aβ40 peptide. (C) Concentrations of anti-Aβ antibodies were detected after 3rd immunizations in sera from individual mice. Bars indicate average ± SD (n = 5 per group, **P ≤ 0.01, ****P ≤ 0.0001).
Table 2. Liposomal dose formulations composition and characterization
Figure 2. Humoral and cellular immune responses generated by different formulations of protein- and DNA-based AD epitope vaccines, AV-1982R and AV-1959D, respectively. (A) Concentrations of anti-Aβ antibodies were detected after 3rd immunizations in sera from individual mice. (B) Cellular responses are specific to Thep protein, but not Aβ40 peptide. Splenocytes were re-stimulated with 10 µg/mL Thep protein or Aβ40 peptide. Bars indicate average ± SD. Statistical differences in all groups were calculated relative to Liposomes/AV-1982R/AV-1959D immunized group using two-tailed t test (n = 6 per group, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).
